Good morning :)
$
₹
Solid Biosciences LLC

Solid Biosciences LLC

SLDB

NASDAQ
Asset Logo

Solid Biosciences LLC

SLDB

NASDAQ
$5.782.28% (-0.13)
$
₹
$5.782.28% (-0.13)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $634.8M the stock is ranked 3037

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.73
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.89
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 14 analysts reports

Buy
14 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+216.12%

Earnings Growth

+13.06%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.68
80.68
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.28
27.28
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.90
29.90
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
662.28%
662.28%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 216.12% growth, versus a trailing 3-year CAGR of 40.60%.

2026
Current$5.92Baseline
Analyst Target - 1 year
Target$18.71+216.12%

All values in $

202220232024202520262027$7.85$12.09$16.34Target+216.12%
2026
Current$5.92Baseline
Analyst Target - 1 year
Target$18.71+216.12%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-2.02Baseline
Forecast for Dec 2026
High$-1.55+23.27%
Average$-1.76+13.06%
Low$-2.39-18.32%

All values in $

202120222023202420252026-10.2-9.82-4.85-3.04-2.02Low-18.32%Average+13.06%High+23.27%
2025
Current$-2.02Baseline
Forecast for Dec 2026
High$-1.55+23.27%
Average$-1.76+13.06%
Low$-2.39-18.32%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-45.7
-49.7
-56.7
-54.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0003.12000000
Net Income-24.30-25.07-32.72-42.59-39.28-39.48-45.77-49.78-56.73-54.79
Net Profit Margin----1363.54%------
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Solid Biosciences LLC -1.73-
AbbVie Inc80.6850.450.53
Amgen Inc27.2817.562.28
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare SLDB with any stock or ETF
Compare SLDB with any stock or ETF
Comparing from
SLDB
ABBV
AMGN
Loading...

Frequently asked questions

  1. Solid Biosciences LLC (SLDB) share price today is $5.78 as of October 27, 2026 at 12:18 AM IST. The stock touched a day high of $6.06 and a day low of $5.78.

  2. Solid Biosciences LLC stock trades on NASDAQ under the ticker symbol SLDB.

  3. Solid Biosciences LLC's market capitalization is $634.77M as of October 27, 2026 at 12:18 AM IST.

  4. Solid Biosciences LLC's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Solid Biosciences LLC's price-to-book (P/B) ratio is 1.73 as of October 26, 2026.

  6. Yes, You can buy Solid Biosciences LLC shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Solid Biosciences LLC shares in three steps: 1. Search Solid Biosciences LLC on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Solid Biosciences LLC trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Solid Biosciences LLC (SLDB) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.7286 shares at the current price of $5.78.

Loading...